BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23553917)

  • 1. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 Aug; 60(8):1325-32. PubMed ID: 23553917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).
    Houghton PJ; Kurmasheva RT; Kolb EA; Gorlick R; Maris JM; Wu J; Tong Z; Arnold MA; Chatterjee M; Williams TM; Smith MA
    Pediatr Blood Cancer; 2015 Jul; 62(7):1214-21. PubMed ID: 25809532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
    Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
    Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.
    Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gorlick R; Kolb EA; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2012 Jun; 58(6):916-23. PubMed ID: 21584937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
    Reynolds CP; Kang MH; Maris JM; Kolb EA; Gorlick R; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2015 Nov; 62(11):1897-905. PubMed ID: 26154614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.
    Gorlick R; Kolb EA; Keir ST; Maris JM; Lock RB; Carol H; Reynolds CP; Kang MH; Billups CA; Collins J; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2016 Mar; 63(3):443-50. PubMed ID: 26797892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.
    Carol H; Gorlick R; Kolb EA; Morton CL; Manesh DM; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak A; Hickson I; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA; Lock R
    Pediatr Blood Cancer; 2014 Feb; 61(2):245-52. PubMed ID: 24038993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
    Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
    Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions.
    Towle MJ; Nomoto K; Asano M; Kishi Y; Yu MJ; Littlefield BA
    Anticancer Res; 2012 May; 32(5):1611-9. PubMed ID: 22593439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.
    Houghton PJ; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wu J; Smith MA
    Pediatr Blood Cancer; 2010 Jul; 54(7):921-6. PubMed ID: 20166202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2011 Apr; 56(4):595-603. PubMed ID: 21298745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
    Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
    Gorlick R; Kolb EA; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock R; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA
    Pediatr Blood Cancer; 2012 Dec; 59(7):1266-74. PubMed ID: 22315240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.
    Sampson VB; Vetter NS; Zhang W; Patil PU; Mason RW; George E; Gorlick R; Kolb EA
    Oncotarget; 2016 Dec; 7(52):86594-86607. PubMed ID: 27863409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.
    Houghton PJ; Morton CL; Kolb EA; Gorlick R; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Apr; 50(4):799-805. PubMed ID: 17635004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
    Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
    Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.
    Reynolds CP; Kang MH; Carol H; Lock R; Gorlick R; Kolb EA; Kurmasheva RT; Keir ST; Maris JM; Billups CA; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 May; 60(5):791-8. PubMed ID: 23002019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.